BioVersys in the News

BioVersys does have a research laboratory and collaboration with the Institut Pasteur de Lille and is very grateful to be mentioned in their annual report 2021.  If you want to learn more about Institut Pasteur de Lille, click the link below and discover how the teams are mobilized every day to accelerate research and act for the health […]

Antibiotikaresistenzen bleiben weltweit eine wachsende Gefahr. Wie kann ihnen begegnet werden? Experten setzen auf bessere Information, gezielteren Einsatz und neue Wirkstoffe. Doch das Vergütungssystem erschwert deren Markteintritt. Ein Blick nach Großbritannien könnte die Lösung aufzeigen. Curious to read on?Below you will find the link to the full article published by Tagesspiegel Background Kampf gegen Antibiotikaresistenzen: Die

Schon heute sterben mehr Menschen an bakteriellen Infektionskrankheiten als an HIV/Aids oderMalaria. Der Grund: Viele Antibiotika wirken nicht mehr. Wissenschaft ler und Pharmaherstellerfordern nun einen radikalen Politikwechsel: Zugang zu den Medikamenten, Forschungsanreize undVergütungssysteme müssten auf den Kopf gestellt werden. Curious to read on?Below you will find the link to the full article published by Tagesspiegel

Despite the global increase in resistant pathogens, hardly any new antibiotics have come onto the market in recent decades. Marc Gitzinger, CEO of the Basel-based start-up BioVersys, calls for new reimbursement models for antibiotics. Curious to read on?Below you will find the link to the full article published by Handelskammer beider Basel. Antibiotika sind Opfer ihres

Global Research on Antimicrobial Resistance (GRAM), 4-year study reveals 471 million individual records or isolates and 7585 study-location-years’ worth of data have led to the most comprehensive analysis of the burden of AMR ever undertaken. The study shows that in 2019, 4.95 million people died with drug-resistant bacterial infections. Of these, 1.27 million deaths were

BioVersys, ein Spin-off der ETH Zürich in Basel, widmet sich seit zehn Jahren der Bekämpfung von Antibiotikaresistenzen. CEO und Co-Gründer Marc Gitzinger schätzt die Infrastruktur und die attraktive Biotech-Szene, die er am Forschungsstandort Basel vorfindet. Link to Article

The Swiss biotech company is making significant progress in the research and development of treatments to fight bacterial resistance, a real and present Global Health issue. BioVersys has been striving to make new drugs effective against bacterial infections. Antibiotics are among the most important and oldest medical discoveries, saving millions of lives each year. But

BioVersys together with BioSystems Technology and Voxcan announced funding – € 840,000 over a 3-year period – by Eurostars for IMPACT2, a new translational AMR platform that will expedite the development of novel new medicines in the fight against antimicrobial resistance. There is an urgent need for new treatments against untreatable infections caused by drug-resistant

An interesting and informative report on bacteria and antibiotic resistance, including an interview with Marc Gitzinger. The report starts at 10:25 Link to Article

The European Medicines is proposing to update its two existing guidelines on the clinical evaluation of medicines for treating bacterial infections and merge them into a single core document. The new document would clarify, among other things, considerations for the acceptance of single pivotal studies to support infection-site specific indications and pathogen-specific indications. A draft